10x Genomics Q3 2024 GAAP EPS $(0.30) Beats $(0.34) Estimate, Sales $151.654M Miss $158.632M Estimate
Portfolio Pulse from Benzinga Newsdesk
10x Genomics reported a Q3 2024 GAAP EPS of $(0.30), beating the estimate of $(0.34), but sales of $151.654M missed the $158.632M estimate. Sales decreased by 1.30% compared to the same period last year.
October 29, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
10x Genomics reported better-than-expected EPS for Q3 2024, but sales fell short of expectations and decreased year-over-year.
The EPS beat suggests better cost management or operational efficiency, which is positive. However, missing sales estimates and a year-over-year decline in sales could raise concerns about growth prospects. These mixed signals may lead to a neutral short-term stock impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100